Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.